Pfizer, Celltrion say data backs switch to Remicade biosimilar

31st October 2017 Uncategorised 0

Pfizer and Celltrion Healthcare have unveiled new data showing that switching patients with Crohn’s disease from Remicade to biosimilar Inflectra showed comparable efficacy, safety and tolerability over a 24-week period.

More: Pfizer, Celltrion say data backs switch to Remicade biosimilar
Source: News